Abstract: The present invention relates to combinations and pharmaceutical compositions comprising an IGF inhibitor and a chemotherapeutic agent, and their use in treating a proliferative disorder such as cancer (for example a solid cancer such as pancreatic cancer). The invention also provides an IGF inhibitor for use in treating such proliferative disorders in combination with a chemotherapeutic agent, and a chemotherapeutic agent for use in treating such proliferative disorders in combination with an IGF inhibitor and a biomarker for identifying proliferative disorders which have increased responsiveness to the combined treatment.

Abstract: In alternative embodiments, the invention provides methods for regulating or modulating RAF kinases. In alternative embodiments, the invention provides methods for ameliorating, preventing and/or treating diseases, infections and/or conditions having unwanted, pathological or aberrant cell proliferation, or that are responsive to inhibition or arrest of cell growth, by administration of an allosteric RAF inhibitor and/or any agent which prevents localization of RAF to mitotic spindles or mid-bodies.